SCHEMBL733239

SCHEMBL733239

O=C(O)c1cc2c(-c3ccccc3)nn(-c3ccccn3)c2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
KDM4E B2RXH2 5/20 0.62
MAPT P10636 8/20 0.54
RXFP1 Q9HBX9 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
TSHR P16473 3/20 0.48
HPGD P15428 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
USP2 O75604 2/20 0.48
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
PTGER1 P34995 2/20 0.42
HSD17B10 Q99714 2/20 0.41
ESR1 P03372 1/20 0.41
CREBBP Q92793 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731946 0.84 ALDH1A1 (0.70) ALDH1A1KDM4EMAPTSMN1; SMN2TSHR
SCHEMBL31327144 0.84 ALDH1A1 (0.70) ALDH1A1KDM4EMAPTSMN1; SMN2TSHR
SCHEMBL730536 0.83 MAPT (0.73) ALDH1A1KDM4EMAPTRXFP1SMN1; SMN2
SCHEMBL732951 0.81 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTSMN1; SMN2TSHR
SCHEMBL730881 0.80 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTSMN1; SMN2TSHR
SCHEMBL348602 0.77 KDM4E (1.00) ALDH1A1KDM4EMAPTRXFP1SMN1; SMN2
SCHEMBL733174 0.73 KDM4E (0.70) ALDH1A1KDM4EMAPTRXFP1SMN1; SMN2
SCHEMBL6408825 0.72 ALDH1A1 (0.64) ALDH1A1KDM4EMAPTRXFP1SMN1; SMN2
SCHEMBL731118 0.72 L3MBTL1 (0.45) ALDH1A1KDM4EMAPTSMN1; SMN2TSHR
SCHEMBL347512 0.69 LMNA (0.44) ALDH1A1KDM4EMAPTSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 ALDH1A1 113/4885KDM4E 3445/4885MAPT 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.